Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Primary Purpose
Oral Cancer
Status
Not yet recruiting
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)
Doxorubicin chemotherapeutic drug as a positive control
Sponsored by
About this trial
This is an interventional treatment trial for Oral Cancer focused on measuring Tongue, SCC, chemotherapy, Quercetin, PLGA-PEG nanoparticle
Eligibility Criteria
Inclusion Criteria:
- Tongue Squamous cell carcinoma cell lines
- Quercetin drug.
- Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)
- Application of a Quercetin drug as chemotherapeutic drug.
- Detection of Quercetin activity in apoptosis or cytotoxicity/cell viability.
Exclusion Criteria:
- Any cancer cell line other than tongue Squamous cell carcinoma cell lines
- Any use of Quercetin other than chemotherapy.
- Detection of Quercetin activities other than apoptosis or cytotoxicity/cell viability
Sites / Locations
- 11 Saraya El Manial
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Quercetin drug.
Quercetin-encapsulated PLGA-PEG nanoparticles
Doxorubicin chemotherapeutic drug
Arm Description
Outcomes
Primary Outcome Measures
Cytotoxicity/Cell viability.
MTT assay for cellular viability:
The cytotoxic impacts of the tested drugs and Nano QUT-encapsulation will be measured by MTT. The (HNO-97) cells will be cultured in 96-well plates at a density of 5 × 103 cells/well. All drugs with their described concentrations will be added to the media over tongue SCC cell lines. After a day of incubation, the dissolved MTT in PBS will be added to each well at a final concentration of 5 mg/ml, and the samples will be incubated at 37 °C for 4h. Water-insoluble dark blue formazan crystals that will be formed during MTT cleavage in actively metabolizing cells will then be dissolved in dimethyl sulfoxide (DMSO). Absorbance will be measured at A455 nm, using an ELISA microplate reader
Apoptosis.
Annexin V and propidium iodide (PI) stains will be used in the determination of apoptosis after treatment with the free, nano counterpart of QUT and free Dox post 24h of their incubation over the HNO-97 cell line. The apoptotic analysis will be dedicated to differentiating between early and late apoptotic cells, as well as necrotic cells. The apoptosis of the treated and untreated HNO-97 line with the proposed free, nano counterpart of Nano-QUT and Dox will be analyzed by flow cytometer apparatus
Secondary Outcome Measures
Gene expression of (BCL-2) .
Following treatment with the proposed free DOX, free and Nano-QUT formulations for 24 h, the cells are harvested, lysed and tested with RT-PCR using specific primers to estimate the fold change of the apoptotic signals (BCL-2 and Bax) and survival pathway (Expression of PI3K gene). GAPDH will be used as a housekeeping gene to normalize the level of target gene expression.
Gene expression of ( Bax gene)
Following treatment with the proposed free DOX, free and Nano-QUT formulations for 24 h, the cells are harvested, lysed and tested with RT-PCR using specific primers to estimate the fold change of the apoptotic Bax gene
survival pathway (Expression of pi3k gene)
Following treatment with the proposed free DOX, free and Nano-QUT formulations for 24 h, the cells are harvested, lysed and tested with RT-PCR using specific primers to estimate the fold change of survival pathway (Expression of pi3k gene)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05456022
Brief Title
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Official Title
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 2022 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Squamous cell carcinoma (SCC) is the most common oral cavity carcinoma. Conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations.The major obstacle of using current anticancer drugs is; first the non-specific tissue distribution, as these drugs are unable to distinguish between normal and cancer cells.Quercetin is a bioactive flavonoid having strong antioxidant properties. .Among all the nanomaterials, polymeric nanoparticles are of significant interest for drug delivery applications due to many unique features of nanoparticle polymers.This is the first study to investigate the anticancer effects of (Quercetin) either free or encapsulated by PLGA-PEG NPs in tongue squamous cell carcinoma (TSCC) cell line.
Detailed Description
Squamous cell carcinoma (SCC) is the most common oral cavity carcinoma. Conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations. The major obstacle of using current anticancer drugs is; first the non-specific tissue distribution, as these drugs are unable to distinguish between normal and cancer cells. Quercetin is a bioactive flavonoid having strong antioxidant properties. It is naturally present in a wide variety of fruits and vegetables. Among all the nanomaterials, polymeric nanoparticles are of significant interest for drug delivery applications due to many unique features of nanoparticle polymers. Polymeric nanocarriers have been fabricated from natural and synthetic polymers. Poly ethylene glycol-poly lactide-co-glycolic acid (PEG-PLGA) amphiphilic copolymer is an emergent system because it can be easily synthesized and possesses a lot of good qualities. Several previous in vitro and in vivo studies have evaluated the cytotoxic effects of quercetin and have revealed that it decreases cell viability and increases cell apoptotic rate in OSCC. However, the anti-cancer property of quercetin in tongue squamous cell carcinoma (TSCC) has not been studied yet. This is the first study to investigate the anticancer effects of (Quercetin) either free or encapsulated by PLGA-PEG NPs in tongue squamous cell carcinoma (TSCC) cell line.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oral Cancer
Keywords
Tongue, SCC, chemotherapy, Quercetin, PLGA-PEG nanoparticle
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1000000 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Quercetin drug.
Arm Type
Experimental
Arm Title
Quercetin-encapsulated PLGA-PEG nanoparticles
Arm Type
Experimental
Arm Title
Doxorubicin chemotherapeutic drug
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
Other Intervention Name(s)
Citrus bioflavonoid, Sophoretin; Meletin; Quercetine; Xanthaurine; Quercetol; Quercitin; Quertine; Flavin
Intervention Description
Appearance (Color) Conforms Yellow Appearance (Form) Powder
1H NMR Spectrum Conforms to Structure Loss on Drying < 4 % _ Purity (HPLC) > 95 %
Intervention Type
Drug
Intervention Name(s)
Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)
Intervention Description
Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
Intervention Type
Drug
Intervention Name(s)
Doxorubicin chemotherapeutic drug as a positive control
Intervention Description
Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
Primary Outcome Measure Information:
Title
Cytotoxicity/Cell viability.
Description
MTT assay for cellular viability:
The cytotoxic impacts of the tested drugs and Nano QUT-encapsulation will be measured by MTT. The (HNO-97) cells will be cultured in 96-well plates at a density of 5 × 103 cells/well. All drugs with their described concentrations will be added to the media over tongue SCC cell lines. After a day of incubation, the dissolved MTT in PBS will be added to each well at a final concentration of 5 mg/ml, and the samples will be incubated at 37 °C for 4h. Water-insoluble dark blue formazan crystals that will be formed during MTT cleavage in actively metabolizing cells will then be dissolved in dimethyl sulfoxide (DMSO). Absorbance will be measured at A455 nm, using an ELISA microplate reader
Time Frame
within 1 week after cell line propagation
Title
Apoptosis.
Description
Annexin V and propidium iodide (PI) stains will be used in the determination of apoptosis after treatment with the free, nano counterpart of QUT and free Dox post 24h of their incubation over the HNO-97 cell line. The apoptotic analysis will be dedicated to differentiating between early and late apoptotic cells, as well as necrotic cells. The apoptosis of the treated and untreated HNO-97 line with the proposed free, nano counterpart of Nano-QUT and Dox will be analyzed by flow cytometer apparatus
Time Frame
within 1 week after cell line propagation
Secondary Outcome Measure Information:
Title
Gene expression of (BCL-2) .
Description
Following treatment with the proposed free DOX, free and Nano-QUT formulations for 24 h, the cells are harvested, lysed and tested with RT-PCR using specific primers to estimate the fold change of the apoptotic signals (BCL-2 and Bax) and survival pathway (Expression of PI3K gene). GAPDH will be used as a housekeeping gene to normalize the level of target gene expression.
Time Frame
within 1 week after cell line propagation
Title
Gene expression of ( Bax gene)
Description
Following treatment with the proposed free DOX, free and Nano-QUT formulations for 24 h, the cells are harvested, lysed and tested with RT-PCR using specific primers to estimate the fold change of the apoptotic Bax gene
Time Frame
within 1 week after cell line propagation
Title
survival pathway (Expression of pi3k gene)
Description
Following treatment with the proposed free DOX, free and Nano-QUT formulations for 24 h, the cells are harvested, lysed and tested with RT-PCR using specific primers to estimate the fold change of survival pathway (Expression of pi3k gene)
Time Frame
within 1 week after cell line propagation
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Tongue Squamous cell carcinoma cell lines
Quercetin drug.
Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)
Application of a Quercetin drug as chemotherapeutic drug.
Detection of Quercetin activity in apoptosis or cytotoxicity/cell viability.
Exclusion Criteria:
Any cancer cell line other than tongue Squamous cell carcinoma cell lines
Any use of Quercetin other than chemotherapy.
Detection of Quercetin activities other than apoptosis or cytotoxicity/cell viability
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hana'a Algadi, P.h.D
Phone
01116360252
Email
hanaahezamalgadi@yahoo.com
Facility Information:
Facility Name
11 Saraya El Manial
City
Cairo
Country
Egypt
12. IPD Sharing Statement
Learn more about this trial
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
We'll reach out to this number within 24 hrs